MA52216B1 - Mirikizumab pour le traitement de la colite ulcéreuse - Google Patents
Mirikizumab pour le traitement de la colite ulcéreuseInfo
- Publication number
- MA52216B1 MA52216B1 MA52216A MA52216A MA52216B1 MA 52216 B1 MA52216 B1 MA 52216B1 MA 52216 A MA52216 A MA 52216A MA 52216 A MA52216 A MA 52216A MA 52216 B1 MA52216 B1 MA 52216B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- ulcerative colitis
- mirikizumab
- antibody
- disease
- Prior art date
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
- 229950009792 mirikizumab Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne de manière générale le traitement de la colite ulcéreuse avec un anticorps anti-IL-23pl9, en particulier des schémas posologiques pour le traitement de la maladie.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 | |
| PCT/US2019/024633 WO2019191464A1 (fr) | 2018-03-30 | 2019-03-28 | Méthodes de traitement de la colite ulcéreuse |
| EP19722256.5A EP3773715B1 (fr) | 2018-03-30 | 2019-03-28 | Mirikizumab pour le traitement de la colite ulcéreuse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52216A MA52216A (fr) | 2021-02-17 |
| MA52216B1 true MA52216B1 (fr) | 2024-07-31 |
Family
ID=66429483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52216A MA52216B1 (fr) | 2018-03-30 | 2019-03-28 | Mirikizumab pour le traitement de la colite ulcéreuse |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12152072B2 (fr) |
| EP (2) | EP4327866A3 (fr) |
| JP (4) | JP7119114B2 (fr) |
| KR (1) | KR102552693B1 (fr) |
| CN (1) | CN111936165A (fr) |
| AU (2) | AU2019243283C1 (fr) |
| BR (1) | BR112020018099A2 (fr) |
| CA (1) | CA3095297A1 (fr) |
| DK (1) | DK3773715T3 (fr) |
| EA (1) | EA202091989A1 (fr) |
| ES (1) | ES2983809T3 (fr) |
| FI (1) | FI3773715T3 (fr) |
| HR (1) | HRP20240904T1 (fr) |
| HU (1) | HUE067445T2 (fr) |
| IL (2) | IL277514B2 (fr) |
| LT (1) | LT3773715T (fr) |
| MA (1) | MA52216B1 (fr) |
| MD (1) | MD3773715T2 (fr) |
| MX (1) | MX2020010269A (fr) |
| PL (1) | PL3773715T3 (fr) |
| PT (1) | PT3773715T (fr) |
| RS (1) | RS65661B1 (fr) |
| SG (1) | SG11202009526RA (fr) |
| SI (1) | SI3773715T1 (fr) |
| TW (2) | TWI837532B (fr) |
| UA (1) | UA128578C2 (fr) |
| WO (1) | WO2019191464A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
| BR112022015996A2 (pt) * | 2020-02-14 | 2022-10-11 | Janssen Biotech Inc | Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| US12258393B2 (en) | 2020-05-21 | 2025-03-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| MX2023007933A (es) * | 2021-01-06 | 2023-09-15 | Abbvie Inc | Métodos para tratar la enfermedad de crohn y la colitis ulcerosa. |
| US20220372129A1 (en) * | 2021-05-20 | 2022-11-24 | Janssen Biotech, Inc. | Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha |
| US20240254217A1 (en) * | 2021-05-28 | 2024-08-01 | Eli Lilly And Company | Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis |
| WO2024110898A1 (fr) * | 2022-11-22 | 2024-05-30 | Janssen Biotech, Inc. | Méthode de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23 |
| WO2024191771A1 (fr) | 2023-03-10 | 2024-09-19 | Eli Lilly And Company | Méthodes de traitement de la colite ulcéreuse |
| WO2024255867A1 (fr) * | 2023-06-16 | 2024-12-19 | 信达生物制药(苏州)有限公司 | Utilisation d'un anticorps de sous-unité anti-interleukine 23p19 recombinant dans le traitement d'une maladie intestinale inflammatoire |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101252951B (zh) * | 2005-06-30 | 2011-12-21 | 森托科尔公司 | 抗il-23抗体、组合物、方法和用途 |
| ES2517420T3 (es) | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
| PL2059534T3 (pl) | 2007-02-23 | 2012-09-28 | Merck Sharp & Dohme | Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej |
| EP2352762A1 (fr) * | 2008-11-03 | 2011-08-10 | Schering Corporation | Biomarqueurs de maladie inflammatoire de l'intestin et procédés apparentés du traitement |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| WO2019171252A1 (fr) * | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 |
-
2019
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 EP EP23215626.5A patent/EP4327866A3/fr active Pending
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 CA CA3095297A patent/CA3095297A1/fr active Pending
- 2019-03-28 IL IL312807A patent/IL312807B1/en unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/fr active Application Filing
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/fr active Active
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103A1/en active Pending
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52216B1 (fr) | Mirikizumab pour le traitement de la colite ulcéreuse | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| JOP20190194B1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| EA201792182A1 (ru) | Композиции и способы для лечения анемии | |
| EA202092435A3 (ru) | Моноклональные антитела против bcma | |
| EA201992546A1 (ru) | Средства на основе антител к cd33 | |
| MX2019001814A (es) | Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| DOP2018000014A (es) | Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina | |
| EA201791005A1 (ru) | Улучшенные антитела против il-6 | |
| MA44645B1 (fr) | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 | |
| MA45999A (fr) | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b | |
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| MA55558A (fr) | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
| EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких |